AustralianSuper’s Haemonetics HAE Stock Holding History

AustralianSuper’s Portfolio HAE Stock Details HAE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-150,559	Closed	-$13.5M	–	162
2020 Q2	$13.5M	Buy	+150,559	New	+$15.2M	0.13%	84

Other funds holding HAE

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AustralianSuper's HAE Position: Q3 2020 in Review

AustralianSuper sold out of Haemonetics (HAE) in Q3 2020, closing a stake of 150,559 shares — an estimated $13.5M sold.

AustralianSuper first reported a position in HAE in Q2 2020 and held it in 1 quarter. The position peaked at $13.5M in Q2 2020. 268 funds tracked by Wall St. Rank hold HAE as of Q3 2020.

AustralianSuper reported no remaining Haemonetics position as of Q3 2020 after selling out during the quarter.
AustralianSuper sold 150,559 Haemonetics shares in Q3 2020, an estimated $13.5M.
AustralianSuper first reported a position in Haemonetics in Q2 2020 and held it in 1 quarter.
AustralianSuper's Haemonetics position peaked at $13.5M in Q2 2020.
268 funds tracked by Wall St. Rank held Haemonetics as of Q3 2020.

Based on AustralianSuper's 13F filing for Q3 2020, filed 16 Nov 2020.